Novartis terminates agreement with Mesoblast (ASX:MSB)

Company News

by Lauren Evans

Pharmaceutical company Novartis has terminated the agreement with medicine developer Mesoblast (ASX:MSB) prior to closing.

A deal was struck with Novartis last year, which included an initial payment of $US50 million from Novartis. The agreement was dependent on successful outcomes from the clinical trial, which involved treatment for Covid-19-related acute respiratory distress syndrome (ARDS).

Mesoblast said the observed mortality reduction with remestemcel-L in patients aged under 65 in the completed Covid ARDS trial, despite having missed the primary endpoint, is considered by Mesoblast to be a sufficiently strong signal to support pursuing an emergency use authorisation, the most direct path to market.

The company also said Covid-19 is likely to remain a serious global problem and to provide a major commercial opportunity for Mesoblast, with a steady state of intensive care unit ARDS patients irrespective of vaccines and anti-viral treatments.

Shares in Mesoblast (ASX:MSB) are trading 15.6 per cent lower at $1.44. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.